Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95
Authors:
- Wolfgang DörffelWDWolfgang Dörffel
- Ursula RühlURUrsula Rühl
- Heike LüdersHLHeike Lüders
- Alexander ClaviezACAlexander Claviez
- Marion AlbrechtMAMarion Albrecht
- Jos BökkerinkJBJos Bökkerink
- Harald HolteHHHarald Holte
- Jonas KarlenJKJonas Karlen
- Georg MannGMGeorg Mann
- Heinz MarciniakHMHeinz Marciniak
- Felix NiggliFNFelix Niggli
- Kjeld SchmiegelowKSKjeld Schmiegelow
- 20 April 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (12) , 1562-1568
Abstract
Purpose: To minimize the risk of late effects in pediatric Hodgkin lymphoma (HL) by omitting radiotherapy (RT) in patients in complete remission (CR) after chemotherapy and reducing the standard radiation dose to 20 Gy in patients in incomplete remission.Patients and Methods: Between 1995 and 2001, 925 patients with classical HL (cHL) were registered from seven European countries in German Society of Pediatric Oncology and Hematology Hodgkin Lymphoma Trial 95. Patients in treatment group 1 (TG1; early stages) received two cycles of vincristine, prednisone, procarbazine, and doxorubicin or vincristine, prednisone, etoposide, and doxorubicin chemotherapy; additional two or four cycles of cyclophosphamide, vincristine, prednisone, and procarbazine were added in TG2 (intermediate stages) or TG3 (advanced stages), respectively. Patients in CR (assessed by computed tomography or magnetic resonance imaging) did not undergo RT. Those with tumor volume reduction more than 75% received reduced involved-field RT with 20 Gy and an additional 10- or 15-Gy boost only for larger residuals.Results: Rates of overall survival, progression-free survival (PFS), and event-free survival at 10 years were (± SE) 96.3% ± 0.6%, 88.2% ± 1.1%, and 85.4% ± 1.3%, respectively. PFS for TG1 patients without or with RT was 97.0% ± 2.1% versus 92.2% ± 1.7% (P = .214) but was unsatisfactory for nonirradiated patients in TG2 (68.5% ± 7.4% v 91.4% ± 1.9%; P < .0001), with similar but not significant results in TG3 (82.6% ± 5.4% v 88.7% ± 2.0%, P = .259). Reduction of the standard radiation dose from 25 to 20 Gy did not increase failure rate.Conclusion: RT can be omitted in early stage HL in so defined CR following this chemotherapy. RT with 20(−35) Gy proved to be sufficient in patients with incomplete remission following chemotherapy.Keywords
This publication has 34 references indexed in Scilit:
- Preliminary Results of the Multicenter Trial GPOH-HD 95 for the Treatment of Hodgkin’s Disease in Children and Adolescents: Analysis and OutlookKlinische Padiatrie, 2003
- Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multicenter trial DAL-HD-90.Radiotherapy and Oncology, 2002
- High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90Journal of Clinical Oncology, 1999
- 11 Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric study groupBailliere's Clinical Haematology, 1996
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Reduzierung der Strahlendosen auf 20-30 Gy im Rahmen einer kombinierten Chemo-/Radiotherapie beim Morbus Hodgkin im KindesalterKlinische Padiatrie, 1994
- Thyroid Diseases after Treatment of Hodgkin's DiseaseNew England Journal of Medicine, 1991
- The Challenge of Pediatric Hodgkin's Disease–Where is the Balance Between Cure and Long-Term Toxicity?: A report of the West German multicenter studies DAL-HD-78, DAL-HD-82 and DAL-HD-85Leukemia & Lymphoma, 1990
- The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: An analysis of 271 non-laparotomised cases (BNLI report no. 22)Clinical Radiology, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958